

Search History

L1 STR
 L2 (66)SEA SSS FUL L1
 L3 (27)SEA ABB=ON PLU=ON L2
 L4 24 SEA ABB=ON PLU=ON L3 AND (PRY<=2003 OR AY<=2003 OR PY<=2003)

 ACT SPI981HC1AU/A

L5 STR
 L6 (66)SEA SSS FUL L5
 L7 (27)SEA ABB=ON PLU=ON L6
 L8 (24)SEA ABB=ON PLU=ON L7 AND (PRY<=2003 OR AY<=2003 OR PY<=2003)

L9 (130)SEA ABB=ON PLU=ON LANDAU S?/AU
 L10 (4538)SEA ABB=ON PLU=ON MILLER C?/AU
 L11 (77)SEA ABB=ON PLU=ON THOR K?/AU
 L12 3 SEA ABB=ON PLU=ON (L9 OR L10 OR L11) AND L8

FILE 'HCAPLUS' ENTERED AT 11:28:34 ON 02 JAN 2008

L13 21 SEA ABB=ON PLU=ON L4 NOT L12

Author Search

=> FILE HCAPLUS

FILE 'HCAPLUS' ENTERED AT 11:28:34 ON 02 JAN 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications.

The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 2 Jan 2008 VOL 148 ISS 1

FILE LAST UPDATED: 1 Jan 2008 (20080101/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.


This file contains CAS Registry Numbers for easy and accurate substance identification.

'OBI' IS DEFAULT SEARCH FIELD FOR 'HCAPLUS' FILE

=> D QUE L12

L5

STR



Structure attributes must be viewed using STN Express query preparation:
Uploading strA.str

```

1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:Atom  8:Atom  9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom 21:Atom

```

5-HT3 receptor antagonist and noradrenaline reuptake inhibitor combination

INVENTOR(S): Landau, Steven B.; Miller, Cheryl L.
; Fraser, Matthew O.
PATENT ASSIGNEE(S): Dynogen Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 104 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004089288	A2	20041021	WO 2004-US10088	20040402 <--
WO 2004089288	A3	20050421		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004227945	A1	20041021	AU 2004-227945	20040402 <--
CA 2519379	A1	20041021	CA 2004-2519379	20040402 <--
US 2004209869	A1	20041021	US 2004-817332	20040402 <--
US 6846823	B2	20050125		
EP 1539181	A2	20050615	EP 2004-758741	20040402 <--
EP 1539181	B1	20070627		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
JP 2006522144	T	20060928	JP 2006-509595	20040402 <--
EP 1795196	A2	20070613	EP 2007-5612	20040402 <--
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LI, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
AT 365554	T	20070715	AT 2004-758741	20040402 <--
US 2005020577	A1	20050127	US 2004-863771	20040607 <--
US 2005026909	A1	20050203	US 2004-863770	20040607 <--
US 7115606	B2	20061003		
US 2005272719	A1	20051208	US 2005-122940	20050504 <--
US 2005282799	A1	20051222	US 2005-124580	20050506 <--
AU 2007200317	A1	20070215	AU 2007-200317	20070125
PRIORITY APPLN. INFO.:				
			US 2003-461022P	P 20030404 <--
			US 2003-496502P	P 20030820 <--
			US 2004-536341P	P 20040113
			AU 2004-227945	A3 20040402
			EP 2004-758741	A3 20040402
			US 2004-817332	A1 20040402
			WO 2004-US10088	W 20040402
			US 2004-863771	A1 20040607

OTHER SOURCE(S): MARPAT 141:343543

ED Entered STN: 22 Oct 2004

AB The invention relates to a method of treating at least one symptom of a lower urinary tract disorder in a subject in need of treatment wherein the symptom is selected from the group consisting of urinary frequency, urinary urgency, urinary urge incontinence, nocturia and enuresis. The method comprises


administering to a subject in need of treatment a therapeutically effective amount of a compound that has 5-HT₃ receptor antagonist activity and NorAdrenaline Reuptake Inhibitor (NARI) activity. The invention further relates to a method of treating at least one symptom of a lower urinary tract disorder in a subject in need of treatment wherein the symptom is selected from the group consisting of urinary frequency, urinary urgency, urinary urge incontinence, nocturia and enuresis, comprising coadministering to said subject a first amount of a 5HT₃ antagonist and a second amount of a NARI, wherein the first and second amts. together comprise a therapeutically effective amount or are each present in a therapeutically effective amount Administration of MCI-225 to rat or cat models of overactive bladder caused a significant dose-dependent increase in bladder capacity.

IT 99487-25-9

RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(5-HT₃ receptor antagonist and noradrenaline reuptake inhibitor combination for treating lower urinary tract disorders)

RN 99487-25-9 HCAPLUS

CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)-
(CA INDEX NAME)



L12 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:610068 HCAPLUS Full-text

DOCUMENT NUMBER: 141:134099

TITLE: Method of treating nausea, vomiting, or retching by
administering a 5-HT₃ receptor antagonist and
noradrenaline reuptake inhibitor

INVENTOR(S): Landau, Steven B.; Miller, Cheryl L.
; Thor, Karl Bruce

PATENT ASSIGNEE(S): Dynogen Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 66 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004062624	A2	20040729	WO 2004-US809	20040113 <--
WO 2004062624	A3	20050407		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ				
AU 2004204827	A1	20040729	AU 2004-204827	20040113 <--

Serial No.:10/757,981

CA 2512022	A1	20040729	CA 2004-2512022	20040113 <--
US 2004147510	A1	20040729	US 2004-757981	20040113 <--
EP 1567163	A2	20050831	EP 2004-701830	20040113 <--
EP 1567163	B1	20070411		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

BR 2004006748	A	20051220	BR 2004-6748	20040113 <--
CN 1750827	A	20060322	CN 2004-80004249	20040113 <--
JP 2006516977	T	20060713	JP 2006-500937	20040113 <--
AT 359079	T	20070515	AT 2004-701830	20040113 <--
NZ 541009	A	20070928	NZ 2004-541009	20040113 <--
ES 2285407	T3	20071116	ES 2004-4701830	20040113 <--
US 2004254171	A1	20041216	US 2004-846978	20040514 <--
US 2004254172	A1	20041216	US 2004-846979	20040514 <--
US 7094786	B2	20060822		
IN 2005DN02961	A	20070413	IN 2005-DN2961	20050704 <--
MX 2005PA07379	A	20060210	MX 2005-PA7379	20050707 <--

PRIORITY APPLN. INFO.:

US 2003-440076P	P	20030113 <--
US 2003-492478P	P	20030804 <--
US 2004-757981	A1	20040113
WO 2004-US809	W	20040113

OTHER SOURCE(S): MARPAT 141:134099

ED Entered STN: 30 Jul 2004

AB The invention relates to a method of treating nausea, vomiting, retching or any combination thereof in a subject in need of treatment. The method comprises administering to a subject in need of treatment a therapeutically effective amount of a compound that has 5-HT₃ receptor antagonist activity and NorAdrenaline Reuptake Inhibitor (NARI) activity. The invention further relates to a method of treating nausea, vomiting, retching or any combination thereof in a subject in need thereof, comprising coadministering to said subject a first amount of a 5-HT₃ antagonist and a second amount of a NARI, wherein the first and second amts. together comprise a therapeutically effective amount or are each present in a therapeutically effective amount. In addition, the method of the invention comprises administering a NARI alone. A pharmaceutical composition comprising: (a) a first amount of a 5-HT₃ receptor antagonist; and (b) a second amount of a noradrenaline reuptake inhibitor is also claimed.


IT 99487-25-9

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)

(method of treating nausea, vomiting, or retching by administering a
5-HT₃ receptor antagonist and noradrenaline reuptake inhibitor)

RN 99487-25-9 HCAPLUS

CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)-
(CA INDEX NAME)



L12 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:610067 HCAPLUS Full-text

DOCUMENT NUMBER: 141:134098

TITLE: Method of treating functional bowel disorders by administering a 5-HT3 receptor antagonist and noradrenaline reuptake inhibitor

INVENTOR(S): Landau, Steven B.

PATENT ASSIGNEE(S): Dynogen Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 81 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004062623	A2	20040729	WO 2004-US807	20040113 <--
WO 2004062623	A3	20050609		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ				
AU 2004204825	A1	20040729	AU 2004-204825	20040113 <--
AU 2004204825	B2	20070719		
CA 2512983	A1	20040729	CA 2004-2512983	20040113 <--
US 2004147509	A1	20040729	US 2004-757364	20040113 <--
EP 1558081	A2	20050803	EP 2004-701811	20040113 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2004006749	A	20051220	BR 2004-6749	20040113 <--
CN 1750759	A	20060322	CN 2004-80004227	20040113 <--
JP 2006516976	T	20060713	JP 2006-500936	20040113 <--
NZ 541008	A	20070928	NZ 2004-541008	20040113 <--
US 2004254168	A1	20041216	US 2004-838789	20040503 <--
US 2004254169	A1	20041216	US 2004-841317	20040507 <--
US 2004254170	A1	20041216	US 2004-841318	20040507 <--
US 2004259862	A1	20041223	US 2004-841319	20040507 <--
US 2005032780	A1	20050210	US 2004-866593	20040611 <--
US 2005192270	A1	20050901	US 2005-119357	20050429 <--
IN 2005DN02967	A	20070413	IN 2005-DN2967	20050704 <--
MX 2005PA07381	A	20060210	MX 2005-PA7381	20050707 <--
ZA 2005005817	A	20060426	ZA 2005-5817	20050720 <--
US 2006217391	A1	20060928	US 2006-441905	20060526 <--
PRIORITY APPLN. INFO.:			US 2003-440077P	P 20030113 <--
			US 2003-492480P	P 20030804 <--
			US 2004-757364	A1 20040113
			WO 2004-US807	W 20040113
			US 2005-119357	A1 20050429

OTHER SOURCE(S): MARPAT 141:134098

ED Entered STN: 30 Jul 2004

AB The invention relates to a method of treating functional bowel disorders in a subject in need of treatment. The method comprises administering to a subject in need of treatment a therapeutically effective amount of a compound that has 5-HT3 receptor antagonist activity and NorAdrenaline Reuptake Inhibitor (NARI) activity. The invention further relates to a method of treating a functional bowel disorder in a subject in need thereof, comprising coadministering to said subject a first amount of a 5-HT3 antagonist and a second amount of a NARI, wherein the first and second amts. together comprise a therapeutically effective amount or are each present in a therapeutically effective amount In

addition, the method of the invention comprises administering a NARI alone. The functional bowel disorders which can be treated according to the method of the invention include IBS, functional abdominal bloating, functional constipation and functional diarrhea. A pharmaceutical composition comprising: (a) a first amount of a 5-HT₃ receptor antagonist; and (b) a second amount of a noradrenaline reuptake inhibitor is also claimed.

IT 99487-25-9

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(method of treating functional bowel disorders by administering a 5-HT₃ receptor antagonist and noradrenaline reuptake inhibitor)

RN 99487-25-9 HCAPLUS

CN Thieno[2,3-d]pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)-
(CA INDEX NAME)

